All six evaluable patients in Alpha Tau Medical’s study of its Alpha DaRT therapy for recurrent glioblastoma had an objective response, the company said. Five had no measurable tumor remaining at the treated site, while the sixth had a 58% reduction in tumor measurements.
Alpha Tau shares rose 13% to $15.15 in premarket trading on Monday. At Friday’s close, the stock had more than doubled year to date.
The company said no unanticipated serious adverse events had occurred in the trial. One grade 3 serious adverse event, reported in May, was a seizure in a patient with a history of seizures.
Chief Executive Uzi Sofer said the results had exceeded the company’s expectations, particularly given the difficulty of treating glioblastoma. He described recurrence as “virtually inevitable.” Alpha Tau plans to keep monitoring patients as their scans mature and continue enrollment toward 20 participants. The company expects that enrollment to support an application to market Alpha DaRT for glioblastoma.
Comments (0)
No comments yet. Be the first!